These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1290619)

  • 1. Clinical experience with angiotensin II receptor antagonists.
    Brunner HR; Christen Y; Munafo A; Lee RJ; Waeber B; Nussberger J
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):243S-246S. PubMed ID: 1290619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
    Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II antagonists DuP 753 and TCV 116.
    Brunner HR; Delacrétaz E; Nussberger J; Burnier M; Waeber B
    J Hypertens Suppl; 1994 Nov; 12(9):S29-34. PubMed ID: 7884581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.
    Weber MA
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):247S-251S. PubMed ID: 1290620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The angiotensin II type 1 receptor blocker losartan in clinical practice: a review.
    Gavras HP; Salerno CM
    Clin Ther; 1996; 18(6):1058-67; discussion 1057. PubMed ID: 9001823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
    Triggle DJ
    Clin Ther; 1995; 17(6):1005-30. PubMed ID: 8750395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
    Christen Y; Waeber B; Nussberger J; Porchet M; Borland RM; Lee RJ; Maggon K; Shum L; Timmermans PB; Brunner HR
    Circulation; 1991 Apr; 83(4):1333-42. PubMed ID: 2013151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renin-angiotensin system blockade. What can be expected from angiotensin II antagonists?].
    Waeber B; Nussberger J; Brunner H
    Rev Prat; 1992 Oct; 42(16):2066-8. PubMed ID: 1485114
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
    Morita O; Kushida H; Kunihara M
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):880-7. PubMed ID: 7564332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiotensin II receptor antagonists].
    Bornkessel B
    Med Monatsschr Pharm; 1995 Jun; 18(6):148-51. PubMed ID: 7609710
    [No Abstract]   [Full Text] [Related]  

  • 12. Losartan: first of a new class of angiotensin antagonists for the management of hypertension.
    Carr AA; Prisant LM
    J Clin Pharmacol; 1996 Jan; 36(1):3-12. PubMed ID: 8932538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
    Krasnikova TL
    Klin Med (Mosk); 1996; 74(3):17-21. PubMed ID: 8926692
    [No Abstract]   [Full Text] [Related]  

  • 14. [Angiotensin-II receptor blockers].
    Metelitsa VI
    Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837
    [No Abstract]   [Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
    Munafo A; Christen Y; Nussberger J; Shum LY; Borland RM; Lee RJ; Waeber B; Biollaz J; Brunner HR
    Clin Pharmacol Ther; 1992 May; 51(5):513-21. PubMed ID: 1587065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
    Goldberg AI; Dunlay MC; Sweet CS
    Am J Cardiol; 1995 Apr; 75(12):793-5. PubMed ID: 7717281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the chemical development of angiotensin II receptor antagonists.
    Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angioedema associated with angiotensin II receptor antagonist losartan.
    Sharma PK; Yium JJ
    South Med J; 1997 May; 90(5):552-3. PubMed ID: 9160080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.